恒瑞医药公告称，近日其HRS - 4642注射液被药审中心纳入突破性治疗品种名单。该注射液为化学药品 1类，拟定用于携带KRASG12D突变的晚期或转移性胰腺癌一线治疗，2025年12月24日申请。它是公司 自研的KRASG12D抑制剂，国内外尚无同类药物获批上市，相关项目累计研发投入约2.54亿元。药品研 发受多因素影响，存在不确定性风险，公司会推进项目并披露进展。 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of HRS-6093 tablets, a novel and efficient oral KRASG12D inhibitor that specifically targets the KRASG12D mutation protein to exert anti-tumor effects [1] Company Summary - The company is set to initiate clinical trials for HRS-6093 tablets in the near future following regulatory approval [1] - HRS-6093 is characterized as a new, selective oral medication aimed at treating tumors associated with the KRASG12D mutation [1]